A fixed-dose combination (FDC) of an antispasmodic (Camylofin) and a non-steroidal anti-inflammatory drug (NSAID) (Diclofenac). It is primarily used for the symptomatic relief of acute, painful spasms of smooth muscle in the gastrointestinal, biliary, and genitourinary tracts, where inflammation is a contributing factor. The combination provides synergistic action: Camylofin relieves spasm, while Diclofenac reduces inflammation and pain at the source.
Adult: One tablet (Camylofin 25mg + Diclofenac 25mg) every 6-8 hours as needed for pain. The total daily dose of Diclofenac should not exceed 150mg (i.e., 6 tablets of this combination). Should be taken with or after food.
Note: Take with a full glass of water, with food or milk to minimize gastrointestinal irritation. Do not crush or chew. The tablet should be swallowed whole. Use only for acute episodes; duration should not exceed 7 days without physician reassessment.
Camylofin is a synthetic anticholinergic agent that acts as a competitive antagonist at muscarinic (M3) receptors on smooth muscle cells, leading to direct relaxation. Diclofenac is a potent NSAID that inhibits the cyclooxygenase (COX) enzymes, COX-1 and COX-2, thereby reducing the synthesis of prostaglandins (PGs), thromboxanes, and prostacyclins from arachidonic acid. The reduction in PGs at the site of injury/inflammation decreases pain, fever, and inflammatory response.
Pregnancy: Category C (first and second trimester): Use only if potential benefit justifies potential fetal risk. Diclofenac may cause premature closure of ductus arteriosus. Category D (third trimester): Contraindicated. Avoid use, especially after 30 weeks gestation.
Driving: May cause dizziness, blurred vision, or drowsiness. Patients should not drive or operate machinery until they know how the medication affects them.
| Other NSAIDs (e.g., Aspirin, Ibuprofen, Naproxen) | Increased risk of GI toxicity (ulcers, bleeding) and renal impairment. | Major |
| Anticoagulants (Warfarin, NOACs like Apixaban) | Diclofenac inhibits platelet function and may increase risk of bleeding. Pharmacokinetic interaction possible. | Major |
| ACE Inhibitors (e.g., Ramipril), ARBs (e.g., Telmisartan), Diuretics | Diclofenac reduces the antihypertensive and natriuretic effect. Increased risk of renal impairment. | Major |
| Lithium | Diclofenac can decrease renal clearance of Lithium, leading to toxicity. | Major |
| Methotrexate | Diclofenac may decrease renal clearance of Methotrexate, increasing toxicity risk. | Major |
| Corticosteroids (e.g., Prednisolone) | Increased risk of GI ulceration and bleeding. | Major |
| Anticholinergics (e.g., Atropine, Trihexyphenidyl) | Additive anticholinergic side effects with Camylofin (dry mouth, constipation, urinary retention, blurred vision). | Moderate |
| CYP2C9 Inhibitors (e.g., Fluconazole, Amiodarone) | May increase Diclofenac plasma levels and toxicity. | Moderate |
| SSRIs (e.g., Sertraline, Fluoxetine) | Increased risk of upper GI bleeding. | Moderate |
| Antacids | May reduce absorption of Diclofenac. Separate administration by 2 hours. | Minor |
Same composition (Camylofin (25mg) + Diclofenac (25mg)), different brands: